UNSPSC 51101676: Parvaquone

This classification denotes an antimalarial agent with the molecular formula C16H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A2BH18685W, chemically known as 1,4-naphthalenedione, 2-cyclohexyl-3-hydroxy- but generally known as parvaquone, which bears US NIH Compound Identifier 71825. European Medicines Agency schedules Parvaquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09634MIG.

UNSPSC 51101676 Parvaquone is a Commodity code that nominally describes a specific veterinary pharmaceutical product, but recent state and local procurement activity under this code shows minimal relevance to the code's stated scope. The recent opportunities tagged to this code instead span naloxone distribution systems, therapeutic pharmacy initiatives for prescription fulfillment, emergency medical and first aid supplies for fire rescue operations, and multi-source generic pharmaceuticals and OTC products through cooperative purchasing — none of which are parvaquone or closely related veterinary medicines. The issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and multistate cooperative purchasing alliances administering contracts across multiple jurisdictions. The mismatch between the code's nominal definition and the actual work being solicited suggests either tagging inconsistency within state and local procurement systems or that parvaquone itself sees negligible solicitation activity at the state and local level.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida posted an IFB on June 30, 2026 for naloxone and drug deactivation systems (due July 26, 2026), the Texas Health and Human Services Commission issued an RFI on April 3, 2026 to explore direct-to-manufacturer prescription programs, the City of Tampa's Purchasing Department solicited medical and first aid supplies for its Fire Department Rescue Division via sealed bid (due March 13, 2026, with an estimated contract value of $700,000), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon (proposals due March 26, 2026). The code shows no recent activity specifically aligned with parvaquone procurement.